July 27, 2015ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy
2015 Stockholder Annual Meeting
Isis Scientists Identify a New Antisense Drug Candidate for the Treatment of Patients with the Autosomal Dominant Retinitis Pigmentosa
We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »
No upcoming events at this time...